CureLab Oncology

Recent Finacing

Equity

Recent Raise

$3M

CureLab develops a p62/SQSTM1 plasmid therapeutic platform, operating CureLab Oncology to run clinical trials in human cancers (TNBC, platinum‑resistant ovarian) and CureLab Veterinary for pet oncology and inflammatory diseases.

Founded 2000

Massachusetts, United States

11-50

Private

curelaboncology.com

Highlights

Focus Areas

Biotechnology

Health Care

Oncology

Therapeutics

Financials

$3M

Total Raised

1

Funding round

Team

Upgrade to view the team

See the team members at CureLab Oncology.